Related Experiment Video
Updated: Aug 14, 2025

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Pediatric ANCA vasculitis: clinical presentation, treatment, and outcomes in a French retrospective study
Sarah-Louisa Mahi1, Siamak Bahram2, Jérôme Harambat3
1Service de Pédiatrie 1, CHU University Hospital Hautepierre, 1, Avenue Molière, 67098, Strasbourg, France.
Insights
Pediatric ANCA vasculitis shows increased incidence and frequent severe ENT involvement. Despite treatment changes, kidney outcomes remain poor, highlighting the need for further research into optimal therapies for children.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Nephrology
Background:
- Pediatric ANCA-associated vasculitis (AAV) is rare with limited pediatric data.
- Increasing incidence and evolving treatments like rituximab necessitate updated outcome analysis.
- This study addresses the scarcity of information on AAV in children.
Purpose of the Study:
- To characterize current pediatric AAV.
- To analyze management strategies and outcomes.
- To evaluate the impact of recent therapeutic trends.
Main Methods:
- Retrospective study over 9 years.
- Involved 46 children across 14 French centers.
- Described clinical/laboratory features, treatments, and kidney outcomes.
Main Results:
- P-ANCA positivity linked to higher relapse risk.
- Frequent and severe ENT involvement noted in children compared to adults.
- Poor kidney outcomes persisted (54.8% CKD at 1 year), with low mortality (6.5%).
Conclusions:
- Long diagnosis times persist; P-ANCA is a significant relapse marker.
- Treatment shifted towards rituximab, away from cyclophosphamide.
- Kidney outcomes remain poor, underscoring the need for prospective studies on optimal therapies.
Background:
Pediatric ANCA vasculitis is a rare group of diseases with a scarcity of data in children. Annual incidence appeared to increase in the last several years, placing higher interest in the clinical and therapeutical outcomes of the disorder. Also, the growing use of rituximab questions the latest outcomes in these diseases. We therefore conducted a retrospective study to better understand the current characteristics, management, and the latest outcomes of the disorder.
Methods:
We conducted a 9-year retrospective study of 46 children in 14 different centers across France to describe their clinical and laboratory presentations, therapeutic regimens, and kidney outcome.
Results:
P-ANCA appeared to be a potential marker for higher relapse risk. Compared to adults, we found that ear-nose-throat presentations were frequent (45.7%) and more severe. Despite an evolution in the treatment management, kidney outcome remained poor with a substantial proportion of chronic kidney disease (54.8% at 1 year). Mortality stays low with 3 patients (6.5%) deceased at the end of our study.
Conclusion:
Clinical presentation was as previously described and time to diagnosis remains long. P-ANCA is a statistically significant marker for increased relapse risk. We observed a modification in the treatment regimens over the past several years with a growing use of rituximab and a decreasing use of cyclophosphamide. Despite these changes, kidney outcome remains poor and prospective studies should be conducted to assess the most appropriate therapeutic modality for each patient. A higher resolution version of the Graphical abstract is available as Supplementary information.
More Related Videos
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Nephrotic Syndrome I : Introduction

